Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...

John Kenney Jr., MD, Lifetime Achievement Award and Lectureship recipient Pearl E. Grimes, MD, FAAD, delivered a tribute to her predecessor as she discussed the history and advancements of vitiligo.

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The market sentiment in the next few months is likely to be quite positive for Pfizer. Read why I maintain my strong buy ...

In this analysis presented at the American Academy of Dermatology annual meeting, serious adverse events were low, unrelated ...

Janus kinase (JAK) inhibitors look to be a good treatment option for the newly recognized, rare autoimmune disease known as ...

JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and cancers added to its label in 2019. Now, a study designed to prove its safety ...

The Medicare Part D redesign under the Inflation Reduction Act (IRA) is also expected to hurt sales of Pfizer’s higher-priced drugs like Vyndaqel, Ibrance and Xeljanz in 2025. However ...

including first-in-class JAK inhibitor Xeljanz (tofacitinib) for rheumatoid arthritis & ulcerative colitis, first-in-class Janus kinase 1 (JAK1) inhibitor Cibinqo (abrocitinib) for atopic ...

However, sales of some key drugs like Prevnar, Xeljanz and Ibrance and new RSV vaccine, Abrysvo declined in the quarter. Seagen drugs contributed $915 million to the top line in the fourth quarter ...